A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

por Winer, Eric S., DeAngelo, Daniel J.
Publicado 2018

A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia

por Maniaci, Breanna N., Chung, Jooho, Sanz-Altamira, Pedro, DeAngelo, Daniel J., Maxson, Julia E.
Publicado 2022

Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia

por Hathorn, Kelly E., Luskin, Marlise R., Caton, Michael Travis, DeAngelo, Daniel J., Saltzman, John R.
Publicado 2019

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

por Chen, Joseph, Haughey, May, Vandendries, Erik, DeAngelo, Daniel J., Kantarjian, Hagop M., Ruiz‐Garcia, Ana
Publicado 2020

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials

por Hantel, Andrew, Luskin, Marlise R., Garcia, Jacqueline S., Stock, Wendy, DeAngelo, Daniel J., Abel, Gregory A.
Publicado 2021

Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration

por Nauffal, Mary, Werner, Lillian, Ni, Jian, Stone, Richard M., DeAngelo, Daniel J., McDonnell, Anne M.
Publicado 2019

Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021

por Mughal, Tariq I., Psaila, Bethan, DeAngelo, Daniel J., Saglio, Giuseppe, Van Etten, Richard A., Radich, Jerald P.
Publicado 2021

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

por Akahane, Koshi, Sanda, Takaomi, Mansour, Marc R., Radimerski, Thomas, DeAngelo, Daniel J., Weinstock, David M., Look, A. Thomas
Publicado 2015

SYK Regulates mTOR Signaling in AML

por Carnevale, Julia, Ross, Linda, Puissant, Alexandre, Banerji, Versha, Stone, Richard M., DeAngelo, Daniel J., Ross, Kenneth N., Stegmaier, Kimberly
Publicado 2013

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

por Cortes, Jorge E., Apperley, Jane F., DeAngelo, Daniel J., Deininger, Michael W., Kota, Vamsi K., Rousselot, Philippe, Gambacorti-Passerini, Carlo
Publicado 2018

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

por Schimmer, Aaron D., Raza, Azra, Carter, Thomas H., Claxton, David, Erba, Harry, DeAngelo, Daniel J., Tallman, Martin S., Goard, Carolyn, Borthakur, Gautam
Publicado 2014

Insulin receptor substrate 1 is a substrate of the Pim protein kinases

por Song, Jin H., Padi, Sathish K. R., Luevano, Libia A., Minden, Mark D., DeAngelo, Daniel J., Hardiman, Gary, Ball, Lauren E., Warfel, Noel A., Kraft, Andrew S.
Publicado 2016

Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis

por Shimony, Shai, Rozental, Alon, Bewersdorf, Jan P., Goldberg, Aaron D., Stein, Eytan M., Grimshaw, Alyssa A., Stone, Richard M., DeAngelo, Daniel J., Wolach, Ofir, Stahl, Maximilian
Publicado 2022

Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic

por Raman, Hari S., Flamand, Yael, Luskin, Marlise R., DeAngelo, Daniel J., Stone, Richard M., Garcia, Jacqueline S., Wadleigh, Martha, Charles, Anne, Copson, Kevin, Lindsley, R. Coleman, Vedula, Rahul S., Winer, Eric S.
Publicado 2021

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials

por Valtis, Yannis K., Stevenson, Kristen E., Place, Andrew E., Silverman, Lewis B., Vrooman, Lynda M., Gotti, Giacomo, Brunner, Andrew M., Nauffal, Mary, DeAngelo, Daniel J., Luskin, Marlise R.
Publicado 2021

Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequenc...

por Kluk, Michael J., Abo, Ryan P., Brown, Ronald D., Kuo, Frank C., Dal Cin, Paola, Pozdnyakova, Olga, Morgan, Elizabeth A., Lindeman, Neal I., DeAngelo, Daniel J., Aster, Jon C.
Publicado 2015

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO...

por Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M., Jabbour, Elias, Wang, Tao, Liang White, Jane, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
Publicado 2019

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

por DeAngelo, Daniel J., Advani, Anjali S., Marks, David I., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, O’Brien, Susan
Publicado 2020

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years

por Shimony, Shai, Fell, Geoffrey, Chen, Evan C., Tsai, Harrison K., Wadleigh, Martha, Winer, Eric S., Garcia, Jacqueline S., Luskin, Marlise R., Stahl, Maximilian, Neuberg, Donna S., DeAngelo, Daniel J., Lindsley, R. Coleman, Stone, Richard M.
Publicado 2023

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients

por Brusic, Ana, Hainz, Ursula, Wadleigh, Martha, Neuberg, Donna, Su, Mei, Canning, Christine M., DeAngelo, Daniel J., Stone, Richard M., Lee, Jeng-Shin, Mulligan, Richard C., Ritz, Jerome, Dranoff, Glenn, Sasada, Tetsuro, Wu, Catherine J.
Publicado 2012